Freenome
Freenome is a biotech company developing non-invasive blood tests for early cancer detection using its multiomics platform and AI.
Secondary Market Price
How Freenome Measures Up
To help you manage your Freenome equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series F
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Freenome's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Freenome Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Freenome's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Freenome is a biotechnology company developing blood-based tests for the early detection of cancer. Founded in 2014 and headquartered in Brisbane, California, the company utilizes a multiomics platform that combines machine learning with the analysis of biological signals in the blood. Its initial focus is on colorectal cancer and advanced adenomas, with its first product being the SimpleScreen™ CRC blood test. Freenome is also expanding its research into other areas, such as a blood-based screening test for lung cancer through its PROACT LUNG Study. Since its inception, the company has raised over $1.1 billion in funding to support its research and development efforts.
Looking ahead, Freenome has entered into a definitive business combination agreement with Perceptive Capital Solutions Corp, a special purpose acquisition company (SPAC), with plans to become a publicly traded company on the Nasdaq under the ticker symbol 'FRNM' in the first half of 2026. The company has also announced several key partnerships, including a strategic collaboration with Roche to develop and commercialize kitted versions of its tests for international markets. Another recent collaboration with NVIDIA Healthcare aims to leverage advanced AI to improve the analysis of complex biological signals for cancer detection. In addition, Freenome recently presented new clinical data on the performance of an improved version of its colorectal cancer screening test at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
- GV
- Bessemer
- Lightspeed
- Gaingels
- Alexandria Venture
- Polaris
- Samsara BioCapital
- Boxer Capital
- Co-Founder, Gabe Otte
- Co-Founder, Riley Ennis
- Co-Founder, Charles Roberts
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Freenome worth joining?
Deciding to join a startup like Freenome involves evaluating many factors, including the potential value of your equity compensation. Tools like Prospect can help you model the future value of your equity and understand its tax implications, giving you a clearer financial picture.
What should I do with my Freenome stock?
Managing your Freenome stock involves creating a strategy for when to exercise options and how to plan for taxes to maximize your potential returns. You can use a platform like Prospect to develop personalized option exercise strategies and understand the financial outcomes of your decisions.
Can you sell Freenome stock?
As Freenome is a private company, you can typically sell shares during company-approved tender offers or, in some cases, on secondary markets. Prospect offers tools to help you navigate tender offers and decide which shares are the most tax-optimal to sell.
How can I find the value of my Freenome stock?
The value of private stock like Freenome's is formally assessed through a 409A valuation, but its future potential value is what truly matters for your financial planning. To forecast what your shares could be worth, you can use platforms like Prospect, which use predictive models trained on venture capital data.
What is Freenome's equity worth?
The ultimate worth of Freenome's equity depends on future events like an IPO or acquisition, which will determine the final share price. You can model different outcomes and project your potential post-tax earnings using specialized tools from Prospect.
What is Freenome's stock ticker symbol?
Freenome is a private company, so it does not have a stock ticker symbol at this time. Ticker symbols are assigned to companies only when they become publicly traded on a stock exchange.
Can I buy or sell Freenome stock?
Employees can typically "buy" stock by exercising their options, and selling is possible during specific liquidity events like tender offers. Platforms like Prospect provide analysis to help you decide when to exercise and how to approach selling opportunities to minimize your tax burden.
What is the criteria to buy or invest in Freenome stock?
For employees, the primary way to "buy" Freenome stock is by exercising vested stock options granted as part of your compensation package. Understanding the financial implications of exercising is crucial, and services like Prospect can help you create an optimal strategy.
